NewsDialy
is advancing its lead trispecific candidate, APVO451, toward clinical development by optimizing scalable manufacturing processes.
The Seattle-based biotechnology company expects to begin Investigational New Drug enabling studies for the molecule in the first half of 2027.
Trispecific therapies are engineered molecules that combine three distinct functions into a single structure.
Unlike traditional antibody therapies, these candidates are designed to recognize cancer cells, activate immune system attacks, and help overcome the defenses tumors use to survive.
Keep reading